Experts highlight growing complexity of personalized therapy choices for metastatic castration-resistant prostate cancer

Dr. Johann De Bono and Dr. Pedro Barata discuss how treatment decisions for metastatic castration-resistant prostate cancer are becoming more intricate as new radiopharmaceuticals and targeted agents enter the market.

They note that the expanding toolbox offers opportunities for tailored care but also requires clinicians to evaluate multiple factors such as disease biology, prior therapies, and patient preferences.

The conversation emphasizes the need for clear patient selection criteria and thoughtful sequencing to maximize benefit while managing safety.

The experts suggest that ongoing research and multidisciplinary collaboration will be essential to navigate these complexities and improve outcomes for men with advanced prostate cancer.